Miglitol is an
alpha-glucosidase inhibitor that improves post-prandial
hyperglycemia, and it is the only
drug in its class that enters the bloodstream. Anecdotally,
miglitol lowers patient
body weight more effectively than other
alpha-glucosidase inhibitors, but the precise mechanism has not been addressed. Therefore, we analyzed the anti-
obesity effects of
miglitol in mice and in the HB2 brown adipocyte cell line.
Miglitol prevented diet-induced
obesity by stimulating energy expenditure without affecting food intake in mice. Long-term
miglitol treatment dose-dependently prevented diet-induced
obesity and induced mitochondrial gene expression in brown adipose tissue. The anti-
obesity effect was independent of preventing
carbohydrate digestion in the gastrointestinal tract.
Miglitol effectively stimulated energy expenditure in mice fed a high-fat high-monocarbohydrate diet, and
intraperitoneal injection of
miglitol was sufficient to stimulate energy expenditure in mice.
Acarbose, which is a non-absorbable
alpha glucosidase inhibitor, also prevented diet-induced
obesity, but through a different mechanism: it did not stimulate energy expenditure, but caused
indigestion, leading to less energy absorption.
Miglitol promoted
adrenergic signaling in brown adipocytes in vitro. These data indicate that circulating
miglitol stimulates brown adipose tissue and increases energy expenditure, thereby preventing diet-induced
obesity. Further optimizing
miglitol's effect on brown adipose tissue could lead to a novel
anti-obesity drug.